172 related articles for article (PubMed ID: 24085365)
1. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? No].
Gampenrieder SP
Dtsch Med Wochenschr; 2013 Oct; 138(41):2097. PubMed ID: 24085365
[No Abstract] [Full Text] [Related]
2. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes].
Stöger H
Dtsch Med Wochenschr; 2013 Oct; 138(41):2096. PubMed ID: 24085364
[No Abstract] [Full Text] [Related]
3. [Breast pathology 2014].
Kreipe HH
Pathologe; 2014 Feb; 35(1):5-6. PubMed ID: 24496989
[No Abstract] [Full Text] [Related]
4. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
Tas F
Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
[TBL] [Abstract][Full Text] [Related]
5. [Use of polymerase chain reaction (PCR) as an additional diagnostic method in gynecologic oncology].
Czerwenka KF; Zeillinger R; Kury F; Manavi M; Speiser P; Peschke M; Steinhart U; Hosmann JW; Kubista E
Gynakol Rundsch; 1991; 31 Suppl 2():378-9. PubMed ID: 1686430
[No Abstract] [Full Text] [Related]
6. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
7. [Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67].
Christgen M; Winkens W; Kreipe HH
Pathologe; 2014 Feb; 35(1):54-60. PubMed ID: 24414612
[TBL] [Abstract][Full Text] [Related]
8. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
[TBL] [Abstract][Full Text] [Related]
9. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.
Ades F; Zardavas D; Bozovic-Spasojevic I; Pugliano L; Fumagalli D; de Azambuja E; Viale G; Sotiriou C; Piccart M
J Clin Oncol; 2014 Sep; 32(25):2794-803. PubMed ID: 25049332
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
12. [Translational research and diagnostics for breast cancer].
Kreipe HH
Pathologe; 2012 Nov; 33 Suppl 2():282-90. PubMed ID: 23064514
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtyping of breast cancer improves identification of both high and low risk patients.
Rossing M; Østrup O; Majewski WW; Kinalis S; Jensen MB; Knoop A; Kroman N; Talman ML; Hansen TVO; Ejlertsen B; Nielsen FC
Acta Oncol; 2018 Jan; 57(1):58-66. PubMed ID: 29164972
[TBL] [Abstract][Full Text] [Related]
14. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.
Lundberg A; Lindström LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Clin Cancer Res; 2017 Dec; 23(24):7512-7520. PubMed ID: 28972043
[No Abstract] [Full Text] [Related]
15. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
16. [Gene expression analysis in breast cancer. A new diagnostic tool in pathology].
Denkert C
Pathologe; 2013 Sep; 34(5):413-8. PubMed ID: 23934410
[TBL] [Abstract][Full Text] [Related]
17. Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.
Park SJ; Lee MH; Kong SY; Song MK; Joo J; Kwon Y; Lee EG; Han JH; Sim SH; Jung SY; Lee S; Lee KS; Park IH; Lee ES
Breast Cancer Res Treat; 2018 Jul; 170(1):69-76. PubMed ID: 29516374
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic targeting in breast cancer].
Penault-Llorca F
Ann Pathol; 2009 Nov; 29 Spec No 1():S71-3. PubMed ID: 19887259
[No Abstract] [Full Text] [Related]
19. Many Women With the Most Common Form of Breast Cancer Can Skip Chemotherapy: Study finds that approximately 70% of patients with this form of the disease do not need adjuvant chemotherapy.
Cancer; 2018 Aug; 124(16):3281-2382. PubMed ID: 30141836
[No Abstract] [Full Text] [Related]
20. Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer.
Karn T; Metzler D; Ruckhäberle E; Hanker L; Gätje R; Solbach C; Ahr A; Schmidt M; Holtrich U; Kaufmann M; Rody A
Breast Cancer Res Treat; 2010 Apr; 120(3):567-79. PubMed ID: 19455418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
